ReviewThe Lancet. Microbe2022
Access and benefit-sharing by the European Virus Archive in response to COVID-19.
Review in The Lancet. Microbe, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- The PABS system under the pandemic agreement: Current status, controversies in negotiations, and future trends.Biosafety and health · 2026Article
- A roadmap to equity in pandemic preparedness, prevention and response.Journal of global health · 2024Article
- The WHO BioHub system: experiences from the pilot phase.BMJ global health · 2023Article
- The Nagoya Protocol on access and benefit sharing: The neglected issue of animal health.Frontiers in microbiology · 2023Article
- Application of the Nagoya Protocol to veterinary pathogens: concerns for the control of foot-and-mouth disease.Frontiers in veterinary science · 2023Review
- Access and benefit-sharing of the pathogenic microorganisms such as SARS-CoV-2.Biosafety and health · 2022Review
- Harmonizing the COVID-19 sample biobanks: Barriers and opportunities for standards, best practices and networks.Biosafety and health · 2022Article
Corrections and comments
- Erratum issuedCorrection to2022
Authors and funding
6 authors.
Funding
Abstract
Biobanking infrastructures, which are crucial for responding early to new viral outbreaks, share pathogen genetic resources in an affordable, safe, and impartial manner and can provide expertise to address access and benefit-sharing issues. The European Virus Archive has had a crucial role in the global response to the COVID-19 pandemic by distributing EU-subsidised (free of charge) viral resources to users worldwide, providing non-monetary benefit sharing, implementing access and benefit-sharing compliance, and raising access and benefit-sharing awareness among members and users. All currently available SARS-CoV-2 material in the European Virus Archive catalogue, including variants of concern, are not access and benefit-sharing cases per se, but multilateral benefit-sharing has nevertheless occurred. We propose and discuss how a multilateral system enabling access and benefit-sharing from pathogen genetic resources, based on the European Virus Archive operational model, could help bridge the discrepancies between the current bilateral legal framework for pathogen genetic resources and actual pandemic response practices.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.